• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the American Heart Journal published the design of the RE-ALIGN study, a Phase II trial aimed at evaluating the safety and pharmacokinetics of oral Pradaxa (dabigitran etexilate) in patients after heart valve replacement. The study is intended to evaluate Pradaxa as an alternative to warfarin.